Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers-Reference-Cited by-同舟云学术

Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers

Published:2012-04 Issue:4 Volume:23 Page:891-897
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kim S.J.,Nakayama S.,Shimazu K.,Tamaki Y.,Akazawa K.,Tsukamoto F.,Torikoshi Y.,Matsushima T.,Shibayama M.,Ishihara H.,Noguchi S.

Funder

Sysmex Corporation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/4/891/19446229/mdr340.pdf

Reference32 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

2. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009;Goldhirsch;Ann Oncol,2009

3. Prognostic value of proliferation in invasive breast cancer: a review;van Diest;J Clin Pathol,2004

4. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients;Stuart-Harris;Breast,2008

5. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?;Colozza;Ann Oncol,2005

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling key genes in esophageal and lung adenocarcinoma progression: A combined high-throughput analysis and molecular docking approach for targeted therapies;Human Gene;2024-12

2. In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents;International Journal of Molecular Sciences;2023-09-06

3. Phosphorylation of USP29 by CDK1 Governs TWIST1 Stability and Oncogenic Functions;Advanced Science;2023-02-13

4. CDK1 Dysregulation in Breast Cancer;Therapeutic potential of Cell Cycle Kinases in Breast Cancer;2023

5. CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis;Therapeutic potential of Cell Cycle Kinases in Breast Cancer;2023